{
    "symbol": "PYPD",
    "quarter": 2,
    "year": 2022,
    "date": "2022-08-10 21:51:17",
    "content": "  For example, management is making forward-looking statements when it discusses our ongoing clinical trials, our expectations regarding the timing of top-line results from the SHIELD I study and potential NDA submission and MAA filing, potential milestone payments under the license agreement with ADVANZ PHARMA, potential future additional commercial partners and our ability to maximize the value of D-PLEX100, the commercial potential for D-PLEX100, market opportunity in Europe, the strength of our financial position and our expectation that our cash balance, together with the upfront payment from ADVANZ PHARMA and the proceeds from the Kreos loan will be sufficient to fund operations through the end of the second quarter of 2023."
}